(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Inn The executives: A Remunerating Profession Decision for Energetic People- AstraZeneca to invest $2 billion as part of US manufacturing push
- Hilary Duff releases 'Mature,' her 1st song in 10 years
- Top 20 Style Brands for Pioneers
- The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
- The most effective method to Pick the Ideal Lab Precious stone Wedding band
- Well known SUVs With Low Energy Utilization In 2024
- A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- The most effective method to Begin Your Excursion in Gold Venture
